Menu
Search
|

Menu

Close
X

Evoke Pharma Inc EVOK.OQ (NASDAQ Stock Exchange Capital Market)

2.42 USD
+0.00 (+0.00%)
As of Nov 21
chart
Previous Close 2.42
Open 2.42
Volume 1,956
3m Avg Volume 16,632
Today’s High 2.43
Today’s Low 2.41
52 Week High 3.40
52 Week Low 1.86
Shares Outstanding (mil) 16.90
Market Capitalization (mil) 46.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.357
FY17
-0.841
FY16
-1.270
FY15
-1.888
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.37
Price to Sales (TTM)
vs sector
--
20.58
Price to Book (MRQ)
vs sector
8.64
4.23
Price to Cash Flow (TTM)
vs sector
--
21.21
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-118.26
13.58
Return on Equity (TTM)
vs sector
-162.20
15.11

EXECUTIVE LEADERSHIP

Cam Garner
Chairman and Co Founder, Since
Salary: --
Bonus: --
David Gonyer
CEO, Founder, Director, Since 2007
Salary: $362,250.00
Bonus: $152,145.00
Matthew D'Onofrio
Executive Vice President, Chief Business Officer Treasurer, Secretary ,, Since 2010
Salary: $313,875.00
Bonus: $105,462.00
Marilyn Carlson
Chief Medical Officer, Since 2013
Salary: $285,000.00
Bonus: $71,820.00
Todd Brady
Director, Since 2007
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

420 Stevens Ave Ste 370
SOLANA BEACH   CA   92075-2081

Phone: +1858.3451494

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

SPONSORED STORIES